Identification of novel vascular targets in lung cancer by Zhuang, X. et al.
Identification of novel vascular targets
in lung cancer
X Zhuang1,2, J M J Herbert1,3, P Lodhia1, J Bradford4, A M Turner5,6, P M Newby1, D Thickett5, U Naidu5,6,
D Blakey4, S Barry4, D A E Cross4 and R Bicknell*,1,2
1School of Immunity and Infection, Institute for Biomedical Research, College of Medical and Dental Sciences, University of
Birmingham, Edgbaston, Birmingham B15 2TT, UK; 2School of Cancer Sciences, College of Medical and Dental Sciences,
University of Birmingham, Edgbaston, Birmingham B15 2TT, UK; 3Technology Hub Sequencing and Bioinformatics, College of
Medical and Dental Sciences, Birmingham B15, UK; 4AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK;
5School of Clinical and Experimental Medicine, University of Birmingham, QEHB Research Laboratories, Mindelsohn Way,
Birmingham B15 2WB, UK and 6Birmingham Heartlands Hospital, Bordesley Green, Birmingham B9 5SS, UK
Background: Lung cancer remains the leading cause of cancer-related death, largely owing to the lack of effective treatments.
A tumour vascular targeting strategy presents an attractive alternative; however, the molecular signature of the vasculature in lung
cancer is poorly explored. This work aimed to identify novel tumour vascular targets in lung cancer.
Methods: Enzymatic digestion of fresh tissue followed by endothelial capture with Ulex lectin-coated magnetic beads was used to
isolate the endothelium from fresh tumour specimens of lung cancer patients. Endothelial isolates from the healthy and tumour
lung tissue were subjected to whole human genome expression profiling using microarray technology.
Results: Bioinformatics analysis identified tumour endothelial expression of angiogenic factors, matrix metalloproteases and cell-
surface transmembrane proteins. Predicted novel tumour vascular targets were verified by RNA-seq, quantitative real-time PCR
analysis and immunohistochemistry. Further detailed expression profiling of STEAP1 on 82 lung cancer patients confirmed
STEAP1 as a novel target in the tumour vasculature. Functional analysis of STEAP1 using siRNA silencing implicates a role in
endothelial cell migration and tube formation.
Conclusions: The identification of cell-surface tumour endothelial markers in lung is of interest in therapeutic antibody and
vaccine development.
Lung cancer is now the leading cause of cancer mortality in the
UK, accounting for 24% of cancer deaths in men and 21% in
women (Office for National Statistics, 2011). Worldwide rates vary
markedly; overall lung cancer accounted for 18% of all cancer
deaths in 2008 (Ferlay et al, 2010). Rates have been impacted little
by the advances in diagnosis and treatment to date, and in some
groups, such as British women (Office for National Statistics,
2011), they continue to rise. Lung cancer is divided into two broad
categories – non-small cell (NSCLC) and small cell. More than 80%
of lung cancers are NSCLC, which is comprised mostly of
squamous cancers and adenocarcinomas. Key changes over the
past 10 years in NSCLC include the reclassification of tumour types
(Nair et al, 2011), use of biological markers to guide certain
therapies, use of adjuvant therapy after selected complete
resections and advances in selection and planning for surgery
and radiotherapy – concepts that have been reviewed comprehen-
sively elsewhere (Goldstraw et al, 2011). The most promise has
been shown by CT-based screening, though concerns have been
raised about the potential for multiple invasive tests and cost-
effectiveness of the strategy (Bach et al, 2012). Since many patients
present with advanced disease surgery is often impossible, hence
there is a great need for novel therapeutic agents. This is
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particularly important as current first line regimes add little 42
months to the average survival (Goldstraw et al, 2011). In addition,
many therapies are less beneficial (or indeed more harmful) in
squamous tumours, such as the antifolate agent pemetrexed
(Scagliotti et al, 2011), anti-vascular endothelial growth factor
(VEGF) antibody bevacuzimab (Johnson et al, 2004) and tyrosine
kinase inhibitor (TKI) gefitinib (Wang et al, 2012). Selection for
the latter drug usually also involves testing for EGFR mutation
(Wang et al, 2012), meaning that the pool of patients in whom
each drug works is increasingly small. Therefore, the identification
of novel biomarkers or therapeutic targets is a priority for lung
cancer.
A functional vasculature contributes to tumour progression and
malignant cell metastasis. Endothelial cells lining the tumour
vasculature are exposed to molecular factors and mechanical forces
that are absent in healthy tissue. For example, the vasculature in
solid tumours is often in a hypoxic environment (Dachs and
Chaplin, 1998) and is exposed to elevated the levels of hypoxically
induced angiogenic factors such as VEGF (Relf et al, 1997).
Tumour vessels may also be leaky, tortuous, sometimes blind
ended and have poor vascular smooth muscle and pericyte
coverage (Baluk et al, 2005). As a result, the tumour endothelial
transcriptome is markedly different from that in healthy tissue
and provides a unique source for cancer target identification.
In the last decade, attempts to identify tumour endothelial
markers (TEMs) have included construction of SAGE libraries
from freshly isolated endothelium (ST Croix et al, 2000), use of
microarray platforms (Ho et al, 2003), proteomic analysis of
freshly isolated endothelial cell membranes (Ho et al, 2003; Oh
et al, 2004) as well as bioinformatics data mining (Huminiecki
and Bicknell, 2000; Herbert et al, 2008). These efforts identified
several targets including the EDB domain of fibronectin, a series
of numbered TEMs, annexin A and recently CLEC14A reviewed
in Meyer, 2010.
Recent studies have shown that TEMs are often tissue
dependent, and that endothelial transcriptomes have been
documented for colon (Van Beijnum et al, 2006), breast (Bhati
et al, 2008; Jones et al, 2012) and ovarian cancer (Sasaroli et al,
2011). Known TEMs are often weakly expressed in lung tumours
(Mura et al, 2012) and this prompted us to investigate TEMs in the
lung. For successful expression profiling it is essential to obtain a
pure endothelial population. We demonstrate in this study that
rapid tissue digestion followed by magnetic bead isolation yields
pure endothelial isolates. Following expression profiling of
endothelial isolates from NSCLC patient samples, novel cell-
surface targets of lung tumour vasculature were identified,
presenting attractive potential for developing targeted therapies
for lung cancer.
MATERIALS AND METHODS
Ulex-bead isolation. Healthy and tumour lung tissue was
obtained immediately following surgery with full patient consent
and ethics approval (Heartlands Hospital, REC. 07/MRE08/42).
Minced tissue was digested in DMEM containing 2mgml 1
collagenase type V (Sigma, Gillingham, UK), 7.4mgml 1 of
actinomycin (Sigma) and 30 kUml 1 of DNAse I (Qiagen,
Crawley, UK) at 37oC. Endothelial cells were isolated from the
digested cell suspension by positive selection using Ulex europaeus
lectin-coated magnetic beads (Invitrogen, Paisley, UK).
Microarray. RNA extracted from Ulex-bead isolated samples was
converted to cRNA, then subjected to amplification and labelling.
Labelled cRNA samples were then hybridised to an Agilent 4 x 44k
whole human gene expression microarray (Agilent, Wokingham,
UK). The Bioconductor packages preprocess Core and Limma
were used to subtract background and quantile-normalise probe
signal intensities prior to performing differential gene expression
analyses. Principle component analysis (PCA) was performed in R.
RNA-seq. Seventy-nine and 84 million paired end reads
(50 bpþ 35 bp) were sequenced on the SOLiD4 2nd generation
sequencer (Applied Biosystems, Foster City, CA, USA) for
endothelium from fresh tumour and healthy tissue, respectively.
Reads were mapped to the Human genome (University California
Santa Cruz, version hg19) with Tophat 1.3.3 (Trapnell et al, 2009).
Default parameters for colour space mapping were used with the
exception of the following: 1 g/–max-multihits was set to 1 to
identify the single best mapped read; 2 library-type was set to fr-
secondstrand to reflect the sequencing library preparation; 3 G
provided Tophat with a model set of gene annotation genome
positions from the Refseq hg19 transcriptome. The Tophat output
bam files were sorted using samtools (Version: 0.1.8, (Li et al,
2009)), and ’HTSeq-count’ version 0.4.7p4 (Anders, 2010) was
used, in conjunction with the Human transcriptome GTF Refseq
version 19, to assign gene counts and produce a tab delimited file
of transcript/gene counts. Differential gene expression analysis and
P-value generation on the count data was carried out using the R
Bioconductor package DESeq v1.5 (Anders and Huber, 2010).
Quantitative real-time PCR. RNA extraction, complementary
DNA preparation and quantitative real-time PCR (qPCR) were
performed using LightCycler real-time quantitative PCR (Roche,
Burgess Hill, UK) by following previously described methods
(Armstrong et al, 2008). The Primer sequences are provided in
Supplementary Table 1. The double delta Ct method was used to
compare the expression levels in tumour relative to healthy
endothelial isolates.
Immunohistochemistry. Immunohistochemistry of placental tis-
sue or lung tumour sections were immunostained with antisera to
the targets (all antisera from Abcam, Cambridge, UK). The
sections were then visualised using ImmPRESS universal antibody
kit and NovaRed chromagen (Vector labs, Burlingame, CA, USA).
Finally, the sections were counterstained with Mayers hematoxylin,
dehydrated and mounted in distyrene–plasticizer–xylene resin.
Functional assay with siRNA knockdown. Transfection with
siRNA and functional assays were performed as previously
described (Armstrong et al, 2008). STEAP1 siRNA duplexes were:
D1: sense: 50-CUAUAUUCAGAGCAAGCUATT-30; anti-sense:
50-UAGCUUGCUCUGAAUAUAGTG-30;
D2: sense: 50-GAAUAAGUGGAUAGAUAUATT-30; anti-sense:
50-UAUAUCUAUCCACUUAUUCCA-30 (Ambion, Chipping Norton,
UK). The open area of the wound was quantified using a cell
intelligence quotient analyzer or Image J software (Image J website,
rsbweb.nih.gov). The effect of STEAP1 knockdown on Matrigel
assays was analysed by Angiogenesis Analyzer for ImageJ.
All images were acquired using a Leica DM IL microscope (Leica,
Milton Keynes, UK) and USB 2.0 2M Xli camera (XL Imaging LLC,
Carrollton, TX, USA).
RESULTS
Isolation of lung endothelium from fresh tissue. Previous
studies have shown that a high purity of endothelial isolates can
be achieved using Ulex-conjugated beads (Jackson et al, 1990) but
has not yet been applied to human lung tissue. Ulex agglutinin I is
a lectin that specifically binds to L-fucose residues present in
glycoproteins on the human endothelial surface (Holthofer et al,
1982). Here we examine this approach for the isolation of
endothelium from fresh lung specimens. Fresh healthy or tumour
lung tissue samples (1–3 g) were processed within 3 h post surgery.
The tumour tissue was resected from the viable region of the
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tumour core and the patient-matched healthy tissue was
resected410 cm away from the tumour core. Endothelial cells
were positively isolated using magnetic beads coupled to Ulex
lectin (workflow illustrated in Figure 1A). To verify endothelial
enrichment, expression of the universal endothelial marker
CD31 was examined by qPCR in the endothelial isolates and
compared with that in the bulk tissue. A 15-fold enrichment of
endothelium was achieved in the bead isolated samples when
compared with whole tumour extracts. Afour-fold enrichment was
seen in endothelial cells isolated from healthy lung (Figure 1B).
The differing fold increase in CD31 seen in healthy and tumour
samples is likely owing to the proportion of endothelial cells being
higher in healthy lung (30%) than in tumours (3%–5%). RNA
integrity analysis of a typical RNA isolate is shown in Figure 1C.
The data confirm that the Ulex-bead isolation approach can
effectively isolate the endothelial population from lung.
Microarray of endothelial isolates from lung cancer patients.
For expression profiling, a microarray analysis was performed on
four pairs of NSCLC patient-matched healthy and tumour lung
endothelial isolates. Clinical and pathologic data was obtained
from Birmingham Heartlands Hospital (Table 1, patients 1–4). A
PCA plot shows variation in both tumour and healthy lung
samples and between the samples of each group. This was to be
expected as samples were collected and extracted from different
patients and statistically significant genes are those that are
consistent across replicate samples. Despite this the tumour and
healthy isolates fall into two discrete groups (Figure 2).
To better understand the role of known angiogenesis-associated
genes in NSCLC, a differential expression analysis was performed
using the programme Limma. The analysis revealed a panel of
known angiogenesis-associated genes including COL1A1, VEGF-A,
TEM7, TNC, EPHB2, IL8, FGF1, ANGPTL2 and TEM8 to be
elevated in lung tumour endothelium (Table 2). As tumour
angiogenesis proceeds by proteolysis of the extracellular matrix
(Sottile, 2004), elevated matrix metalloprotease (MMP) activity is
associated with active angiogenesis and tumour progression. The
analysis also identified a number of MMPs that are upregulated in
lung tumour compared with healthy lung endothelium (Table 3).
Identification and validation of putative tumour vascular targets
in NSCLC. For target identification, differentially expressed genes
from the microarray data were filtered through several selection
criteria: Log2 fold change magnitude41, a P-valueo0.5 and
containing a transmembrane or signal peptide domain, which
generated a list comprised of 584 genes. Twelve target candidates
were chosen for further validation based on additional criteria
including the level of association with endothelial cells, previously
published work, sites of expression and relation to known genes
with interesting functional properties (Table 4). To validate
putative targets, a qPCR was performed on the four pairs of
endothelial isolates used in the microarray. Figure 3 shows that all
candidates had elevated expression in tumour compared with that
in healthy endothelium ranging from a 3-to 35-fold increase in
expression.
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Figure 1. A Ulex-coated magnetic bead isolation achieved substantial
endothelial enrichment and gave good quality RNA. (A) The workflow
of the main steps in Ulex-bead isolation of endothelial cells from
healthy/tumor lung tissue. (B) Confirmation of endothelial enrichment
using the Ulex-beads approach. Real-time PCR using a primer set for
the endothelial marker CD31 was performed on the bead isolated
endothelial cells and bulk tissue. Expression of CD31 in the bead
isolated sample was normalised to that in the bulk tissue (n¼3).
(C) Good quality RNA (RIN47) was obtained from Ulex-bead isolated
endothelial cells from healthy and tumour lung tissue.
ECs¼Endothelial cells.
Table 1. Clinical-pathological data of lung cancer patients
used in the genomic analysis
ID Age Gender
Pack
years
smoked
Histology
of tumour
Tumour
stage Application
1 65 M 15 Squamous T1N0M0 Microarray
2 71 M 40 Squamous T1N0M0 Microarray
3 63 F 17 Squamous T1N1M0 Microarray
4 67 M 50 Squamous T3N0M0 Microarray
5 73 F 25 Adeno T2N0M0 RNA-Seq
6 83 M 35 Adeno T2N1M0 RNA-Seq
7 52 M 25 Adeno T2N1M0 RNA-Seq
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Figure 2. Principle component analysis plot of microarray of the four
pairs of healthy and tumour lung endothelial isolates. A PCA plot
showing that the endothelial transcriptomes of healthy and tumour
lung show a clear difference. The separation between healthy and
tumour lung endothelium was highlighted by dotted lines.
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Expression profiling of lung endothelial isolates by RNA-
seq. RNA-seq using deep sequencing technology provides an in-
depth resolution of RNA snapshots by generating millions of reads
that can be assembled and mapped to a known transcriptome,
allowing the measurement of differential gene expression. RNA-seq
has the advantage of querying novel transcripts and does not rely
on prior knowledge and annotation. Here we used RNA-seq to
verify the genes that had been identified through the microarray
analysis. We note that a lower yield of RNA was obtained from
healthy lung tissue compared with that from tumour. This was
possibly owing to the endothelial cells in healthy lung tissue being
in a quiescent state compared with the active endothelium in
tumours. For this reason, endothelial RNA isolated from three
healthy lung samples (pooled; Table 1, patients 5–7) and one tumour
lung tissue (Table 1, patient 6) were sequenced as one healthy and
one tumour sample on a SOLiD4 sequencer. The differential gene
Table 2. Upregulated angiogenesis-associated genes in lung cancer
Gene ID Gene symbol GenBank accession no. LogFC P-value
Collagen, type I, alpha 1 COL1A1 NM_000088 5.11 0.00
Vascular endothelial growth factor A VEGF-A NM_001025366 2.59 0.00
Plexin domain containing 1 PLXDC1(TEM7) NM_020405 2.04 0.01
Tenascin C TNC NM_002160 1.95 0.01
Eph receptor B2 EPHB2 NM_004442 1.76 0.00
Interleukin 8 IL8 ENST00000401931 1.34 0.16
Fibroblast growth factor 1 (Acidic) FGF1 NM_000800 0.82 0.08
Angiopoietin-like 2 ANGPTL2 NM_012098 0.69 0.40
Anthrax toxin receptor 1 ANTXR1(TEM8) NM_032208 0.65 0.15
Abbreviation: LogFC¼ log2 fold change; TEM¼ tumour endothelial marker. Differential expression analysis of microarray data for the identification of elevated known angiogenesis-associated
genes. Listed genes were ranked by LogFC in descending order.
Table 3. Upregulated matrix metallopeptidases in lung cancer
Gene ID Gene Symbol GenBank accession no. LogFC P-value
Matrix metallopeptidase 11 MMP11 NM_005940 4.10 0.00
Matrix metallopeptidase 9 MMP9 NM_004994 4.00 0.00
Matrix metallopeptidase 12 MMP12 NM_002426 3.80 0.00
Matrix metallopeptidase 7 MMP7 NM_002423 3.29 0.17
Matrix metallopeptidase 1 MMP1 NM_002421 2.49 0.05
Matrix metallopeptidase 3 MMP3 NM_002422 1.81 0.02
Matrix metallopeptidase 10 MMP10 NM_002425 1.74 0.12
Matrix metallopeptidase 14 MMP14 NM_004995 1.55 0.00
Matrix metallopeptidase 13 MMP13 NM_002427 1.21 0.04
Matrix metallopeptidase 2 MMP2 NM_004530 1.03 0.12
Abbreviations: Log FC¼ log fold change; MMP¼matrix metalloprotease. Differential expression analysis of microarray data for the identification of elevated matrix metallopeptidases. Listed
genes were ranked by logFC in descending order.
Table 4. Putative vascular targets in lung cancer
Gene ID Gene Symbol GenBank accession no. LogFC P-value TM
Six transmembrane epithelial antigen of the prostate 1 STEAP1 NM_012449 4.19 0.00 6
Synaptotagmin Xii SYT12 NM_177963 4.16 0.00 1
Gap junction protein, b 2, 26Kda GJB2 NM_004004 4.13 0.00 4
Solute Carrier organic anion transporter family, member 1B3 SLCO1B3 NM_019844 3.65 0.00 11
Baculoviral Iap Repeat containing 5 BIRC5 NM_001012271 3.45 0.00 0
Protocadherin 7 PCDH7 NM_002589 2.29 0.00 1
Prominin 2 PROM2 NM_001165978 2.05 0.00 6
Plexin Domain Containing 1 PLXDC1(TEM7) NM_020405 2.04 0.01 1
Bmp and activin membrane-bound inhibitor homologue BAMBI NM_012342 1.99 0.00 1
Lemur tyrosine kinase 3 LMTK3 NM_001080434 1.94 0.07 2
Trophoblast glycoprotein TPBG NM_006670 1.48 0.03 1
C-Ros oncogene 1 , receptor tyrosine kinase ROS1 ENST00000403284 1.39 0.22 1
Abbreviations: Log FC, log fold change; TEM, tumour endothelial marker. Differential expression analysis of microarray data for the identification of putative vascular targets for lung cancer.
Listed genes were ranked by logFC in descending order.
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expression analysis of the RNA-seq data was performed using the
DESeq v1.5 package (Anders and Huber, 2010). The analysis
confirmed most of the unregulated angiogenesis-associated genes,
MMPs and putative targets identified through the microarray
analysis (Figure 4). Analysis of the RNA-seq data alone generated a
list of 477 genes with the same criterion used in the microarray
analysis for target identification. The intersection of the microarray
and RNA-seq gene pools comprises a list of 122 genes, which
provides a rich source for target identification (Supplementary
Table 2). The discrepancy between the two analyses is likely owing
to the cancer type (squamous vs. adeno) and the individual patient
variability.
Expression of TEM candidates in angiogenic tissue and lung
cancer. To further validate the candidate targets, we investigated
protein expression by immunohistochemistry. We have previously
shown that placental vasculature is a rich source of endothelial gene
expression. Thus, immunohistochemical staining was performed first
on the human placental tissue using antibodies to the lung TEM
targets. Amongst the twelve targets, six genes: ROS1, PCDH7, BIRC5,
STEAP1, GJB2 and PROM2 showed expression in human placental
vessels (Supplementary Figure 1). The tumour and healthy lung tissue
was then immunostained and these six candidates are indeed
overexpressed in the lung tumour vessels, whereas absent or at a
low level in the healthy lung tissue (Figure 5). Some of the targets were
not restricted to the tumour endothelium; for example, ROS1 and
STEAP1 also showed positive expression on some tumour cells or
macrophages and this may be beneficial for developing drugs
targeting the tumour and its vasculature simultaneously. It is also
worth mentioning that other target candidates should not be
completely eliminated for further investigation simply owing to the
lack of antibody reactivity in immunochemistry.
Expression of STEAP1 in lung cancer. We then focused on the
top-ranked target STEAP1. To confirm whether STEAP1 is
differentially expressed in the endothelium within the healthy
and tumour lung tissue, an expression profiling was carried out on
human lung cancer tissues by immunohistochemistry. Eighty-two
patients were examined (Table 5). The intensity of the signal was
classified as absent, low, medium or high. Representative images of
STEAP1 staining in lung cancer are shown in Figure 6A. From the
82 cases examined, a clear overexpression of STEAP1 in tumour
vessels was observed; for example 45% of the vessels highly
expressed STEAP1 in lung cancer vs only 5% in matching healthy
lung. The proportion of vessels that are ‘low’ and ‘no expression’ of
STEAP1 was 77% in healthy lung, but only 14% in lung tumours
(Figure 6B). These data confirm that STEAP1 is differentially
expressed between the tumour and healthy lung vasculature and
presents a possible vascular target for lung cancers.
Function of STEAP1 in endothelial cells. We next used siRNA
knockdown to seek a function of STEAP1 in the endothelial cells.
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Figure 3. Validation of putative lung vascular targets by qPCR.
Quantitative real-time PCR validation of tumour vascular target
candidates in the endothelial cells isolated from the healthy and tumour
lung tissue. Flotillin 2 was used as the house keeping gene to which the
data was normalised. The double delta Ct method was used to
compare the expression levels in tumour relative to healthy endothelial
isolates.
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Figure 4. Confirmation of upregulated angiogenesis-associated
genes, MMP and putative vascular targets in lung cancer by RNA-seq.
Differential gene expression analysis of RNA-seq data confirmed a
panel of elevated angiogenesis-associated genes, MMP genes and
lung cancer vascular target candidates identified through microarray
analysis.
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STEAP1 protein expression was efficiently knocked down by two
independent siRNA duplexes (Figure 7A). Migration of HUVEC
after STEAP1 knockdown was compared with that of mock and
negative siRNA-transfected controls in a scratch-wound assay. At
24 h, control wounds showed 60% closure, whereas in STEAP1
knockdown cells the wound had only closed by 35%–40%
(Figure 7B and C). STEAP1 knockdown also compromised tube
formation on Matrigel. Tubes showed a significant decrease in
mesh size compared with controls (Figure 7D and E).
DISCUSSION
The ineffectiveness of current treatments for NSCLC prompted the
search for alternatives. Although TKIs of EGFR initially showed
promising outcomes in several trials, resistance developed in all the
patients (Lovly and Carbone, 2011). Antiangiogenic/anti-tumour
vascular therapy remains a viable alternative (Vasudev and
Reynolds, 2014). VEGF (receptor) blockers have been used to
treat NSCLC patients in early clinical trials; however, concerns
have arisen from the limited efficacy in achieving tumour
regression and the tendency to develop resistance (Pallis and
Syrigos, 2013). In addition, the lack of effective biomarkers for
patient pre-treated selection, emphasises the need for novel targets
and biomarkers. Our study describes the first molecular profiling
of endothelium from NSCLC patient tissue.
A major obstacle that hinders the expression profiling of in vivo
endothelium is the challenge to obtain pure endothelial isolates.
Favre et al described attempts for mouse lung endothelial isolates,
using the unpurified sample as the control, aimed at identifying
endothelial specific genes (Favre et al, 2003). An effort to isolate
mouse endothelium from a Lewis lung carcinoma tumour model
was reported by Allport and Weissleder, (2003); however, the
isolated endothelial cells were subjected to in vitro culture and only
the characterised angiogenesis genes were investigated (Allport and
Weissleder, 2003). In this study, we demonstrate that the Ulex-
bead isolation approach has proven to be an effective approach to
obtain a pure endothelial population from the human lung. The
purity of the endothelial isolates allows for the first time to
precisely document the transcriptome of the lung vasculature using
microarray analysis and deep sequencing platforms.
Our microarray analysis of endothelial isolates from cancer
patients identified a panel of angiogenesis-associated genes and
MMPs elevated in tumour endothelium, which have potential to be
biomarkers for NSCLC. The elevated MMP2 expression is in
agreement with a reported increased MMP2 level in serum that
was shown to be a predictor of metastasis in NSCLC patients
(Guo et al, 2007). MMP2 and MMP9 have also been reported to
associate with tumour grade in various solid tumours (John and
Tuszynski, 2001). The expression of MMP7 and MMP9 were
previously found to be significantly upregulated in NSCLC
compared with that of healthy lung and benign lung tumours
(Safranek et al, 2009). Although clinical trials investigating
inhibitors targeting multiple MMPs yielded limited efficacy
(Heath et al, 2001; Goffin et al, 2005), possibilities remain to
design drugs that are more specific to those highly expressed
MMPs in NSCLC.
RNA-seq using deep sequencing technology has been inten-
sively applied to molecular profiling of many tissue types and cell
populations from different species (Guduric-Fuchs et al, 2012;
Voellenkle et al, 2012). This work is the first description of RNA-
seq for profiling the endothelium from human lung cancer.
Further, cross referencing the microarray data identified 122 genes
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Figure 5. Validation of putative lung vascular targets by
immunohistochemistry. Identified putative lung TEMs were validated
by immunohistochemistry. Representative immunohistochemistry for
lung vascular target candidates on the healthy and tumour lung tissue.
Table 5. Clinical characteristics of lung cancer patients for
STEAP1 profiling
Patients (n) %
Age 63.8±9.5
Sex
Male 64 78%
Female 18 22%
Histology
Squamous cell carcinoma 47 57.3%
Adenocarcinomas 19 23.2%
Large cell carcinoma 5 6.1%
Bronchioloalveolar carcinoma 7 8.5%
Carcinosarcoma 2 2.4%
Clinical stage
I 34 41.5%
II 35 42.7%
III 13 15.8%
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as lung vascular target candidates. Immunohistochemical analysis
confirmed PCHD7, STEAP1, ROS1, BIRC5, GJB2 and RPOM2 to
be novel tumour vascular targets in NSCLC.
STEAP1 was the first member of a family of metalloreductases
described as a cell-surface antigen in prostate tissue (Hubert et al,
1999; Yang et al, 2001). High STEAP1 expression has been found
in prostate, breast, bladder, colon and ovarian carcinomas and in
Ewing’s sarcoma, (Gomes et al, 2012) whereas low or absent in
healthy human tissues, suggesting that STEAP1 may be a wide
ranging tumour antigen (Hubert et al, 1999). Alves et al (2006)
showed that STEAP1 peptides can be used to stimulate CD8þ T
cells, suggesting that STEAP1 may be a useful target for cancer
immunotherapy. Indeed, Maria de la Luz and colleagues also
showed the efficacy of a vaccine against STEAP1 in prophylactic
and therapeutic tumour models (Garcia-Hernandez Mde et al,
2007). To date, expression of STEAP1 in endothelium has not been
described. Our data have shown for the first time that STEAP1
expression is upregulated in endothelial cells in the vessels of
human lung tumours.
PCDH7 belongs to the protocadherin gene family and encodes a
single-pass transmembrane protein. First reported in 1998, study of
PCDH7 has concentrated on neuronal function (Yoshida et al,
1998; Kim et al, 2007; Blevins et al, 2011), and a role in
endothelium or lung cancer has not been explored. An exception
was a genome-wide genotyping of the frozen tumour tissue from
NSCLC patients that identified five nucleotide polymorphisms
(SNPs) located in PCDH7 that are prognostic for the overall
survival in early-stage NSCLC (Huang et al, 2009). ROS1 is a
proto-oncogene and highly expressed in a variety of tumour cell
lines (Birchmeier et al, 1987; Sharma et al, 1989). ROS1 belongs to
the sevenless subfamily of tyrosine kinase receptors and remains an
orphan receptor. Recently, chromosomal rearrangement of ROS1
was detected in a subpopulation of NSCLC patients (Bergethon
et al, 2012; Janne and Meyerson, 2012). Despite intensive study of
ROS1 in lung cancer, there has been no previous report of its
expression in the tumour endothelium. BIRC5 or survivin, belongs
to a family of inhibitors of apoptosis. BIRC5 inhibits the caspase
activation regulating apoptosis. Disruption of the BIRC5 signalling
pathway leads to tumour cell apoptosis and growth delay. BIRC5
protein is often present in tumour cells and fetal tissues but has
rarely been described in the healthy tissue (Sah et al, 2006). GJB2 is
a transmembrane protein that belongs to the connexin family.
Connexins have a role in many physiological processes and
embryonic development including the microvasculature. Defects in
GJB2 lead to the most common form of congenital deafness (Apps
et al, 2007). Thus, most GJB2 studies have centred on this
pathology. Nevertheless, a recent study reported the expression of
GJB2 in lymphatic endothelium in the mouse embryo, and that the
deletion of GJB2 in mice disrupted the development of lymphatic
vessels and was embryonic lethal (Dicke et al, 2011). PROM2 is a
multi-pass membrane protein and belongs to the prominin family
of pentaspan membrane glycoproteins. PROM2 is at present
comparatively uncharacterised.
Low shear stress and turbulent flow are mechanical factors that
regulate endothelial gene expression (Wasserman and Topper,
2004). Around 600 genes are regulated by shear stress in the
endothelial cell (Ando and Yamamoto, 2009; Mura et al, 2012).
Like the previously described TEMs CLEC14A and Robo4,
STEAP1, PCDH7 and BIRC5 are all upregulated in the
endothelium exposed to reduced shear stress (Bicknell et al,
unpublished data). Reduced blood flow and shear stress may
account for their expression on tumour vessels.
To conclude, our work not only enhances our knowledge of
proteins that are differentially expressed on the lung tumour
endothelium but has also identified several promising biomarkers/
targets for future investigation. Cell-surface expression of some of
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Figure 6. Expression profiling of STEAP1 expression in clinical lung cancer samples. (A) Representative images of STEAP1 in healthy (i–ii) and
tumour (iii–vi) lung tissue; expression level classified as no expression (i), low (ii–iii), medium (iv) and high (v–vi). Images were acquired using an
optical microscope at a magnification of  20. (B) Expression profiling of STEAP1 in clinical samples by immunohistochemistry (n¼ 82).
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these targets, for example STEAP1, will facilitate the pre-clinical
validation with antibodies. Further work is needed to characterise
their functions and their roles in the endothelial biology and
angiogenesis in the lung.
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